Source comparison
BPC-157 for DOMS Recovery: Full Comparison
BPC-157 (subcutaneous) Angiogenesis via VEGF upregulation, fibroblast migration, nitric oxide stabilisation 250–300 mcg daily, subcutaneous, post-training 24–48 hours (cumulative effect over 7–14 days) Enhances structural repair without suppressing hypertrophy
This comparison does not assign a generated winner or score.
- BPC-157 (subcutaneous)
- Angiogenesis via VEGF upregulation, fibroblast migration, nitric oxide stabilisation
- 250–300 mcg daily, subcutaneous, post-training
- 24–48 hours (cumulative effect over 7–14 days)
- Enhances structural repair without suppressing hypertrophy signaling
- Most evidence-supported peptide for tissue repair; requires high-purity formulation
- NSAIDs (ibuprofen, naproxen)
- COX-2 inhibition, prostaglandin suppression
- 400–800 mg ibuprofen as needed
- 30–90 minutes (symptom masking)
- Chronic use blunts muscle protein synthesis and satellite cell activation
- Effective for acute pain but counterproductive for training adaptation
- Contrast water immersion
- Vasoconstriction/vasodilation cycles, lactate clearance
- 3–5 cycles (1 min cold, 1 min warm)
- Immediate to 12 hours
- Neutral. No negative impact on hypertrophy
- Low cost, widely accessible, modest effect size
- Massage therapy
- Mechanical disruption of adhesions, lymphatic drainage
- 20–30 min deep tissue, 24–48 hrs post-training
- 12–24 hours
- Neutral to slightly positive
- Subjective benefit high, but mechanistic support limited
- Active recovery (light cardio)
- Increased blood flow, metabolite clearance
- 15–20 min at 40–50% VO2max
- 6–12 hours
- Positive. Preserves training frequency without overreaching
- Evidence-based, cost-free, universally applicable